CA2150119C
(en)
*
|
1992-11-30 |
2005-03-15 |
Robert C. Cuca |
Tastemasked pharmaceutical materials
|
PT744941E
(pt)
*
|
1994-02-16 |
2003-10-31 |
Abbott Lab |
Processo para preparar formulacoes farmaceuticas de particulas finas
|
US5728403A
(en)
*
|
1994-10-05 |
1998-03-17 |
The Board Of Regents Of The University Of Nebraska |
Coating technology for taste masking orally administered bitter drugs
|
DE29502547U1
(de)
*
|
1995-02-16 |
1995-03-30 |
Röhm GmbH, 64293 Darmstadt |
Thermoplastisches Überzugs- und Bindemittel für Arzneiformen
|
EP0826376B1
(en)
*
|
1995-05-02 |
2007-01-24 |
Taisho Pharmaceutical Co. Ltd |
Composition for oral administration
|
AUPO637197A0
(en)
*
|
1997-04-23 |
1997-05-15 |
F.H. Faulding & Co. Limited |
Taste-masked pharmaceutical compositions
|
DE19617487A1
(de)
†
|
1996-05-02 |
1997-11-06 |
Merck Patent Gmbh |
Geschmacksverbesserung von Arzneimittelwirkstoffen
|
AUPN969796A0
(en)
*
|
1996-05-07 |
1996-05-30 |
F.H. Faulding & Co. Limited |
Taste masked liquid suspensions
|
DE19706978A1
(de)
*
|
1997-02-21 |
1998-08-27 |
Ulrich Dr Posanski |
Kombinationspräparat für oral applizierbare Antibiotika
|
DE19706979A1
(de)
*
|
1997-02-21 |
1998-08-27 |
Lindopharm Gmbh |
Kombinationspräparat für oral applizierbare Erythromycine
|
US20050064033A1
(en)
*
|
1997-04-11 |
2005-03-24 |
Notario Gerard F. |
Extended release formulations of erythromycin derivatives
|
US6010718A
(en)
*
|
1997-04-11 |
2000-01-04 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
US6551616B1
(en)
*
|
1997-04-11 |
2003-04-22 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
US6861411B1
(en)
*
|
1997-12-02 |
2005-03-01 |
Pfizer, Inc. |
Method of treating eye infections with azithromycin
|
KR100514330B1
(ko)
*
|
1997-12-31 |
2006-02-17 |
주식회사 중외제약 |
난용성 약물을 함유하는 코팅정
|
US7122207B2
(en)
*
|
1998-05-22 |
2006-10-17 |
Bristol-Myers Squibb Company |
High drug load acid labile pharmaceutical composition
|
JP3466921B2
(ja)
*
|
1998-06-03 |
2003-11-17 |
大塚製薬株式会社 |
味マスキング医薬製剤
|
WO2000018372A1
(fr)
*
|
1998-09-30 |
2000-04-06 |
Taisho Pharmaceutical Co., Ltd. |
Granules pour preparations orales
|
EP1027885B1
(en)
*
|
1999-02-09 |
2008-07-09 |
Pfizer Products Inc. |
Basic drug compositions with enhanced bioavailability
|
DE19907895A1
(de)
*
|
1999-02-24 |
2000-11-16 |
Paz Arzneimittelentwicklung |
Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
|
CN1343128B
(zh)
*
|
1999-03-17 |
2010-04-21 |
第一制药株式会社 |
药物组合物
|
SI20244A
(sl)
*
|
1999-05-19 |
2000-12-31 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Granulacija v talini
|
IN191239B
(no)
|
1999-06-11 |
2003-10-11 |
Ranbaxy Lab Ltd |
|
US6565882B2
(en)
*
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
CZ20023167A3
(cs)
*
|
2000-02-29 |
2003-10-15 |
Teva Pharmaceutical Industries Ltd. |
Způsob přípravy klaritromycinu a klaritromycinového meziproduktu, v podstatě prostého oximu a farmaceutický prostředek, který jej obsahuje
|
IL151888A0
(en)
*
|
2000-03-28 |
2003-04-10 |
Biochemie Gmbh |
Granulated particles with masked taste
|
US6551617B1
(en)
|
2000-04-20 |
2003-04-22 |
Bristol-Myers Squibb Company |
Taste masking coating composition
|
DK1276470T3
(da)
|
2000-04-20 |
2007-06-18 |
Novartis Ag |
Smagskaskerende overtrækssammensætning
|
WO2001091730A1
(en)
|
2000-05-31 |
2001-12-06 |
Drugtech Corporation |
Mineral supplement
|
AU6068001A
(en)
*
|
2000-06-01 |
2001-12-11 |
Taisho Pharmaceutical Co., Ltd. |
Matrices for oral preparations
|
CA2415643C
(en)
*
|
2000-07-17 |
2010-11-16 |
Yamanouchi Pharmaceutical Co., Ltd. |
Pharmaceutical composition for oral use with improved absorption
|
JPWO2002024167A1
(ja)
*
|
2000-09-19 |
2004-01-29 |
第一製薬株式会社 |
医薬組成物
|
US7510728B2
(en)
|
2000-10-06 |
2009-03-31 |
Takeda Pharmaceutical Company Limited |
Solid preparations
|
US20020068078A1
(en)
*
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
JP2004528272A
(ja)
*
|
2000-10-13 |
2004-09-16 |
アドバンシス ファーマスーティカルス |
持続型放出エリスロマイシン誘導体
|
JP4706096B2
(ja)
*
|
2000-10-23 |
2011-06-22 |
大正製薬株式会社 |
不快な味を呈する塩基性薬物配合製剤
|
WO2002041887A1
(fr)
*
|
2000-11-21 |
2002-05-30 |
Kyorin Pharmaceutical Co., Ltd. |
Preparations seches de sirop
|
US20020197314A1
(en)
*
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
MY129350A
(en)
*
|
2001-04-25 |
2007-03-30 |
Bristol Myers Squibb Co |
Aripiprazole oral solution
|
DK1411899T3
(da)
*
|
2001-08-01 |
2009-06-02 |
Novartis Ag |
Smagsmaskerende sammensætning
|
EP1920766B1
(en)
|
2002-02-01 |
2017-08-23 |
Bend Research, Inc |
Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
MXPA04005647A
(es)
|
2002-02-01 |
2005-03-23 |
Pfizer Prod Inc |
Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo.
|
US20040043073A1
(en)
*
|
2002-06-14 |
2004-03-04 |
Chih-Ming Chen |
Pharmaceutical compositions for drugs having pH-dependent solubility
|
EP1530457B1
(en)
|
2002-08-12 |
2009-09-09 |
Bend Research, Inc. |
Pharmaceutical compositions of drugs in semi-ordered form and polymers
|
AU2003283769A1
(en)
|
2002-12-20 |
2004-07-14 |
Pfizer Products Inc. |
Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
|
US20040146553A1
(en)
*
|
2002-12-23 |
2004-07-29 |
Aventis Pharma S.A. |
Compositions for oral administration of active principles requiring masking of taste
|
KR100508992B1
(ko)
*
|
2003-03-31 |
2005-08-17 |
한국유나이티드제약 주식회사 |
쓴 맛을 개선한 클래리스로마이신 경구용 약제 조성물 및 그의 제조 방법
|
AU2004258944B2
(en)
*
|
2003-07-21 |
2011-02-10 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
CA2533292C
(en)
*
|
2003-07-21 |
2013-12-31 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
CA2533178C
(en)
*
|
2003-07-21 |
2014-03-11 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
EP1653925A1
(en)
|
2003-08-11 |
2006-05-10 |
Advancis Pharmaceutical Corporation |
Robust pellet
|
JP2007502294A
(ja)
|
2003-08-12 |
2007-02-08 |
アドバンシス ファーマスーティカル コーポレイション |
抗生物質製剤、その使用法及び作成方法
|
US7282217B1
(en)
|
2003-08-29 |
2007-10-16 |
Kv Pharmaceutical Company |
Rapidly disintegrable tablets
|
WO2005023184A2
(en)
*
|
2003-08-29 |
2005-03-17 |
Advancis Pharmaceuticals Corporation |
Antibiotic product, use and formulation thereof
|
CA2538064C
(en)
*
|
2003-09-15 |
2013-12-17 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
JP2007511500A
(ja)
*
|
2003-11-14 |
2007-05-10 |
ファイザー・プロダクツ・インク |
肥満治療のためのmtp阻害剤の固体非晶性分散体
|
WO2005053639A2
(en)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Controlled release multiparticulates formed with dissolution enhancers
|
ES2308274T3
(es)
*
|
2003-12-04 |
2008-12-01 |
Pfizer Products Inc. |
Procedimiento para fabricar multiparticulados farmaceuticos.
|
BRPI0417348A
(pt)
*
|
2003-12-04 |
2007-03-13 |
Pfizer Prod Inc |
processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
|
WO2005053652A1
(en)
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
|
US6984403B2
(en)
*
|
2003-12-04 |
2006-01-10 |
Pfizer Inc. |
Azithromycin dosage forms with reduced side effects
|
CN1889931A
(zh)
*
|
2003-12-04 |
2007-01-03 |
辉瑞产品公司 |
利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾-冻凝方法
|
MXPA06005913A
(es)
*
|
2003-12-04 |
2006-06-27 |
Pfizer Prod Inc |
Formas de dosificacion de multiparticulas de azitromicina por procedimientos basados en liquidos.
|
CA2547597A1
(en)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Multiparticulate compositions with improved stability
|
JP2007513937A
(ja)
*
|
2003-12-09 |
2007-05-31 |
ファイザー インコーポレイテッド |
Hivプロテアーゼ阻害剤を含む組成物
|
US7943585B2
(en)
|
2003-12-22 |
2011-05-17 |
Sandoz, Inc. |
Extended release antibiotic composition
|
AU2004308419B2
(en)
*
|
2003-12-24 |
2011-06-02 |
Victory Pharma, Inc. |
Enhanced absorption of modified release dosage forms
|
AP2006003768A0
(en)
|
2004-05-25 |
2006-10-31 |
Pfizer Prod Inc |
TetraazabenzoÄeÜazulene derivatives and analogs tehereof
|
US8420115B2
(en)
|
2004-06-03 |
2013-04-16 |
Taisho Pharmaceutical Co., Ltd. |
Oral preparations and process for production thereof
|
EP1771158A4
(en)
*
|
2004-07-02 |
2008-03-12 |
Advancis Pharmaceutical Corp |
TABLET FOR PULSED DELIVERY
|
US8617604B2
(en)
|
2005-02-03 |
2013-12-31 |
Bend Research, Inc. |
Pharmaceutical compositions with enhanced performance
|
US8778924B2
(en)
*
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
US8183381B2
(en)
*
|
2007-07-19 |
2012-05-22 |
Metabolex Inc. |
N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
|
WO2009085637A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Url Pharma, Inc. |
Amorphous metaxalone and amorphous dispersions thereof
|
DK2280704T3
(en)
*
|
2008-03-31 |
2015-06-29 |
Cymabay Therapeutics Inc |
Oxymethylenarylforbindelser and uses thereof
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
DE102009019268A1
(de)
*
|
2009-04-28 |
2010-11-11 |
Lts Lohmann Therapie-Systeme Ag |
Arzneimittel mit poröser Matrix
|
MX2011013080A
(es)
|
2009-06-16 |
2012-01-20 |
Pfizer |
Formas de dosis de apixaban.
|
US8410127B2
(en)
|
2009-10-01 |
2013-04-02 |
Metabolex, Inc. |
Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
|
JP2013528172A
(ja)
|
2010-05-21 |
2013-07-08 |
ファイザー・インク |
2−フェニルベンゾイルアミド
|
ES2676209T3
(es)
|
2010-06-23 |
2018-07-17 |
Metabolex Inc. |
Composiciones de 5-etil-2-{4-[4-(4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
|
AP2016009407A0
(en)
|
2014-03-17 |
2016-08-31 |
Pfizer |
Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
|
US9867809B2
(en)
|
2015-06-30 |
2018-01-16 |
Kemin Industries, Inc. |
Encapsulated active ingredients for controlled enteric release
|
US10292983B2
(en)
|
2016-08-03 |
2019-05-21 |
Cymabay Therapeutics, Inc. |
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
MX2019010756A
(es)
|
2017-03-10 |
2020-01-20 |
Pfizer |
Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
|
KR102614808B1
(ko)
|
2018-08-31 |
2023-12-19 |
화이자 인코포레이티드 |
Nash/nafld 및 관련 질환의 치료를 위한 조합물
|
KR20220003565A
(ko)
|
2019-04-19 |
2022-01-10 |
화이자 인코포레이티드 |
Pah를 치료하기 위한 항증식제
|
US20220387402A1
(en)
|
2019-05-20 |
2022-12-08 |
Pfizer Inc. |
Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
|
EP3990452A1
(en)
|
2019-06-28 |
2022-05-04 |
Pfizer Inc. |
5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
JP2021134211A
(ja)
|
2020-02-24 |
2021-09-13 |
ファイザー・インク |
Nafld/nashおよび関連疾患の処置のための組合せ
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
CN115209876A
(zh)
*
|
2020-03-11 |
2022-10-18 |
泽井制药株式会社 |
颗粒和使用该颗粒的制剂
|
KR20230011968A
(ko)
|
2020-06-09 |
2023-01-25 |
화이자 인코포레이티드 |
멜라노코르틴 4 수용체 길항제로서의 스피로 화합물 및 그의 용도
|
AU2022403203A1
(en)
|
2021-12-01 |
2024-05-02 |
Pfizer Inc. |
3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
WO2024075051A1
(en)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|
WO2024084360A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
|
US20240182468A1
(en)
|
2022-10-18 |
2024-06-06 |
Pfizer Inc. |
Compounds for the activation of ampk
|
WO2024084363A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Use of patatin-like phospholipase domain-containing protein 3 compounds
|
WO2024118524A1
(en)
|
2022-11-28 |
2024-06-06 |
Cerevel Therapeutics, Llc |
Azaindole compounds and their use as phosphodiesterase inhibitors
|
WO2024127297A1
(en)
|
2022-12-16 |
2024-06-20 |
Pfizer Inc. |
3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof
|